ArticleBMC neurology2025
Lambert-Eaton myasthenic syndrome presenting with occult mediastinal small cell carcinoma and positivity for anti-CV2/CRMP5 and anti-SOX1 antibodies: a case report.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune neuromuscular disorder characterized by proximal muscle weakness, autonomic dysfunction and hyporeflexia. Numerous studies have reported the association of LEMS with anti-SOX1 antibodies and small cell carcinoma, but LEMS with double antibody positivity and cerebellar ataxia accompanied by small cell carcinoma is relatively rare. CASE PRESENTATION: A 56-year-old female patient developed progressive limb weakness in November 2023, with symptoms gradually worsening over six months to include gait instability, impaired grip, chest tightness, dyspnea, dysphagia, and aspiration. Electrodiagnostic testing confirmed Lambert-Eaton myasthenic syndrome (LEMS) with positive VGCC antibodies. Paraneoplastic antibody testing showed positive anti-CV2/CRMP5 antibodies (24 AU) and borderline anti-SOX1 antibodies (9 AU), while other antibodies were negative. Initial imaging (contrast-enhanced chest CT and PET-CT) revealed no abnormalities, but follow-up one year later detected mediastinal small cell lung cancer. The patient underwent three plasma exchange sessions with corticosteroid therapy with limited response, then showed significant improvement after switching to subcutaneous Telitacicept (80 mg) combined with Fampyra Comprimidos and Mycophenolate Mofetil capsules, achieving independent ambulation and normal grip strength with only mild residual limb weakness. The patient has since been transferred to a local hospital for chemotherapy.
conclusionWe find that LEMS with concurrent anti-SOX1 and anti-CV2/CRMP5 positivity manifests as rapid progression, prominent proximal weakness, and potential cerebellar and autonomic involvement. Early and sustained oncological surveillance—particularly of mediastinal lymph nodes—and combined immunotherapeutic strategies can significantly improve neurological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.